{"name":"Alloksys Life Sciences B.V.","slug":"alloksys-life-sciences-b-v","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"bIAP bolus and 8h infusion","genericName":"bIAP bolus and 8h infusion","slug":"biap-bolus-and-8h-infusion","indication":"Treatment of pyroptosis-related diseases","status":"phase_3"},{"name":"placebo bolus and 8h infusion","genericName":"placebo bolus and 8h infusion","slug":"placebo-bolus-and-8h-infusion","indication":"Phase 3 clinical trials","status":"phase_3"}]}],"pipeline":[{"name":"bIAP bolus and 8h infusion","genericName":"bIAP bolus and 8h infusion","slug":"biap-bolus-and-8h-infusion","phase":"phase_3","mechanism":"bIAP is a caspase-1 inhibitor that blocks the activation of inflammatory caspases.","indications":["Treatment of pyroptosis-related diseases"],"catalyst":""},{"name":"placebo bolus and 8h infusion","genericName":"placebo bolus and 8h infusion","slug":"placebo-bolus-and-8h-infusion","phase":"phase_3","mechanism":"This drug is a placebo, meaning it has no active therapeutic effect.","indications":["Phase 3 clinical trials"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxNTEJoeHNLN0Y1aEE0cldNWXFfZDZlUUlFOUxmY0hSS1FsUUNrdHF5V1hBQ3ZiU3QyWjVBaVQzdEk3MzhfMDJpU2hKcm5JblMxdUYxdy1SYVB2ZmZVNDM0ZUZnNVFLTnRtNXNNZGtGQmpiTmV5ZHZtZTA5UE5mMTZERm4xeDJsbmhOVGpGdWNlMTlrYnczbjA4OXlB?oc=5","date":"2026-04-08","type":"pipeline","source":"openPR.com","summary":"Segment Analysis and Major Growth Areas in the Acute Renal Failure (ARF) Market - openPR.com","headline":"Segment Analysis and Major Growth Areas in the Acute Renal Failure (ARF) Market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgJBVV95cUxPa0ZVTHNsZlUyYzRtRnRwY0d2YU9qWE5RQkNNVzloYVB0UlVyR1VqZHYxTGcySlhhaWljd09jM21KUzMtLUlEbHBLcUpjWmxKN29SMWEwQ0dndGlPN3pZMXZ2VmpkME5oNlVEanI3MWxPMWlxeDduRndQWTJYdUQ4VW5zakt1TFByWXB4TldpZnFvSlZ2YzlSYU5ic0J0d082alVUdGtHMkNxNmxjSG5mbHkzN21FcDZnTXpnOWg1LUFwZzRHYk1TMl81ZWR1WjlBWVVjM0NNX2tDeVd4Z3RKcjVYUFNaTDMtTGJpdEg1OVd0VGRSalMydDNJSV8tdEdyUjk3NVFsbktDT1R0VTg1Qko1RXNoQQ?oc=5","date":"2023-08-24","type":"trial","source":"prnewswire.com","summary":"Alloksys reports interim results of its clinical phase IIb trial with Alkaline Phosphatase therapy RESCAP® in critical care patients - prnewswire.com","headline":"Alloksys reports interim results of its clinical phase IIb trial with Alkaline Phosphatase therapy RESCAP® in critical c","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}